Drug duo aims to tackle high blood pressure in obesity

NCT ID NCT07678151

Not yet recruiting Disease control Sponsor: Heart Health Research Center Source: ClinicalTrials.gov ↗

First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This study tests whether combining two medications, empagliflozin and finerenone, can lower blood pressure in adults with obesity and stage 1 hypertension. Participants take the drugs or a placebo daily for 12 weeks. The trial also measures effects on kidney function, inflammation, blood sugar, weight, and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: empagliflozin and finerenone
What this could lead to: If successful, this combination could offer a new treatment option for people with obesity and high blood pressure, potentially providing better heart and kidney protection than current therapies.
What could go wrong: This is a 12-week trial with 260 participants, so results are preliminary. The combination may cause side effects like high potassium, kidney injury, low blood pressure, or low blood sugar.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERTENSION (HTN) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypertensive disorder Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPERTENSION (HTN)

Contacts and locations

Locations

Beijing Anzhen Hospital, Capital Medical University

Beijing, Beijing Municipality, China
Ruyang County People's Hospital

Luoyang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.